Drug intelligence / Profile preview

Jinjuling Capsule

Development stage: Unknown
Lead developer: Changxing Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Jinjuling Capsule (金菌灵胶囊) is a Traditional Chinese Medicine (TCM) natural product developed and manufactured by Zhejiang Changxing Pharmaceutical. The active ingredient is derived from the mycelium of the golden needle mushroom (*Flammulina velutipes*). It is an approved oral capsule formulation primarily indicated for the treatment of chronic hepatitis, serving to provide liver protection and immune support. As a fungal-derived therapeutic, its specific molecular mechanisms and biological targets have not been fully characterized in standard pharmacological terms, which is common for traditional natural product medicines.

Brand names: Jinjuling Capsule金菌灵胶囊
Other names: Jinjuling金菌灵

Beyond the preview

Go deeper on Jinjuling Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jinjuling Capsule.

Explore the full profile